BioSpace News Archive

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that the Company granted an aggregate of 221,900 restricted stock units to thirteen newly-hired employees.

Aurinia Pharmaceuticals Inc. announced that the Company’s Compensation Committee granted 4 new employees inducement stock options to purchase an aggregate of 111,620 common shares, at a per share exercise price of $10.96, the closing price of Aurinia’s common stock on March 31, 2023, and an aggregate of 68,170 inducement restricted stock units.

TCR2 Therapeutics Inc. announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 6,000 shares of TCR2’s common stock to two non-executive new hires.

Merck (NYSE: MRK) today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who are not eligible for cisplatin-containing chemotherapy.

Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock.

MedMira Inc., reported on its financial results for the quarter ended January 31, 2023.

PHC Corporation and NovaScan, Inc. announce the launch of a collaboration through which they will seek to explore the feasibility of MarginScanTM, an investigational “ex vivo” medical device that will seek to support physicians in detecting non-melanoma skin cancers.

iNtRON Biotechnology has announced that iNtRON has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model.

Baxter International Inc. (NYSE:BAX), a leader in solutions to advance surgical innovation, unveiled multiple new additions to its surgical portfolios at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023, taking place April 1 through April 4, 2023.

Following assessment of the primary endpoints of the Phase II/III study, PharmaJet partner Gennova Biopharmaceuticals Limited has submitted data for its mRNA-based Omicron specific Covid-19 booster shot for Emergency Use Authorization (EUA) to the office of the Drug Controller General of India (DCGI).